Clinical trial NCT06272357: The Use of Antiarrhythmic Drugs in Pediatrics
Official title: Clinical Audit on the Use of Antiarrhythmic Drugs in Pediatric Age Group
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Antiarrhythmic Drug Adverse Reaction
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-02-22
Enrollment: 158
Sex: ALL
Minimum age (years): 30
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All Patients with Arrhythmic cardiac diseases admitted at cardiology unit Assiut University Hospital aged from 1 month to 18 years.

Brief summary: A study on the use of antiarrhythmic drugs in pediatric age group, in Assiut University Children's Hospital, a clinical audit

Detailed description: Arrhythmias occur in children and adolescents with congenital heart disease as well as those with structurally normal hearts.

Rhythm disturbances (arrhythmias) are not uncommon in sick children admitted in pediatric intensive care unit. These occur as a result of abnormalities in, or insults to, the cardiac conduction system or heart tissues. A rhythm disturbance in a child should be treated as life threatening emergency.

The generation of the action potential and the regional differences that are observed throughout the heart are the result of the selective permeability of ion channels distributed on the cell membrane.

Abnormalities in surface membrane ion channel function are central to arrhythmogenesis.

Antiarrhythmic medications primarily affect the ion channels in cardiac myocytes that are responsible for generating currents that create the action potential.

By altering the activity of these ion channels, the action potential is changed to reduce the likelihood of sustained arrhythmias.

These drugs are predominantly used in treatment of arrhythmia but in addition they are also used as a treatment of other cardiac and non-cardiac conditions.

For example, Calcium channel blockers have been one of the most widely used classes of antihypertensive agents in the last 20 years.

Carvedilol (a beta blocker agent) can be safely used for treatment of chronic heart dysfunction in pediatric patients with dilated cardiomyopathy.

β-blockers are also an essential component of pharmacologic therapy for children with congestive heart failure.

There is a wide range of antiarrhythmic drugs used in treatment of arrhythmias. The modernized comprehensive classification of both established and potential antiarrhythmic drugs was proposed in 2018 Class 0: HCN channel-mediated pacemaker current (If) block Class I: Antiarrhythmic that affect sodium channels (slow depolarization) Class II: Drugs that counteract the sympathetic nervous system, predominantly beta-blockers Class III: drugs that affect the potassium channels (prolong repolarization) Class IV: Drugs that affect calcium channels (Calcium channel blockers) Class V: mechanically sensitive ion channels, Mechanosensitive channel blockers Class VI: Gap junction channel blockers Class VII: Upstream target modulators.

In this study the aim is to describe the use of Cardiovascular Drugs in Pediatric Cardiology unit Assiut University. As regard: indications of use, proper dosage and proper management of side effects of their use.

Eligibility criteria: Inclusion Criteria:

* All Patients with Arrhythmic cardiac diseases admitted at cardiology unit Assiut University Hospital aged from 1 month to 18 years.
* All patient receiving antiarrhythmic drugs admitted to Assiut University Hospital for Children.

Exclusion Criteria:

• Any patient on drugs other than antiarrhythmics.

Primary outcomes:
measure: Detect the rate of use of antiarrhythmic drugs in pediatrics and the different indications for them other than the control of arrhythmia.
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: